Supplement formulations of estrogen blocker, glycogen manager, and muscle recovery solutions and sublingual therapies for increasing absorption rates thereof. The sublingual delivery systems allow the body to absorb up to 94.9% of each dose directly into the bloodstream, completely bypassing the digestion process. Sublingual delivery (under the tongue) results in potencies 4 to 5 times greater than most capsules and powders. An estrogen blocker solution includes purified water, vegetable glycerin, polypropylene glycol, potassium benzoate, citric acid, calcium D glucarate, 7 keto DHEA, IO3, DIM, nettle root extract, agaricus biporus extract, narigin extract, and quercetin dehydrate. Formulas for glycogen manager, and muscle recovery are also disclosed. The glycogen manager formula includes the effective ingredients phellodendron extract, Banaba extract, Vanadium, and Chromium. A method of use involves taking one or two droppers (1 or 2 ml) of the solution sublingually for 30 seconds, and then swallowing.

Methods and compositions for providing a health benefit to an animal using a nutrient blend. In one embodiment, the method can comprise orally administering a composition comprising at least four of the nutrients selected from the group of walnut, maitake mushroom extract, EGCG, turmeric root powder, lycopene, taurine, EPA, and DHA to the animal.

Methods and compositions for providing a health benefit to an animal using a nutrient blend. In one embodiment, the method can comprise orally administering a composition comprising at least four of the nutrients selected from the group of walnut, maitake mushroom extract, EGCG, turmeric root powder, lycopene, taurine, EPA, and DHA to the animal.

The present invention provides a pharmaceutical composition for the treatment of obesity and fatty liver disease caused due to a high-fat diet, containing, as an active ingredient, the powder of a fruiting body or a mycelium of hybrid mushroom strain GBN2WP0970 having no side effects and an excellent triglyceride absorption inhibitory effect.

The present invention provides a pharmaceutical composition for the treatment of obesity and fatty liver disease caused due to a high-fat diet, containing, as an active ingredient, the powder of a fruiting body or a mycelium of hybrid mushroom strain GBN2WP0970 having no side effects and an excellent triglyceride absorption inhibitory effect.

A pharmaceutical composition containing dry powder of pine (Pinus) needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive, dry extracts of ginger (Zingiber officinale), turmeric (Curcuma longa), white peony (Paeonia), Rhodiola Rosea (Rhodiola Rosea), apricot (Prunus) seed, oyster mushroom (Pleurotus ostreatus), green tea (Camellia sinensis), Ginkgo Biloba (Ginkgo biloba), white pepper, pomegranate (Punica granatum) pulp, medlar (Mespilus germanica), dry powder of pomegranate (Punica granatum) juice and folic acid, in the following ratio of the components in weight % (w %):

TABLE-US-00001 dry powder of pine needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive 6-24 dry extract of ginger 6-25 dry extract of turmeric 5-24 dry extract of white peony 2-20 dry extract of Rhodiola Rosea 2-20 dry extract of apricot seed 5-20 dry extract of oyster mushroom 10-34 dry extract of green tea 12-35 dry extract of Ginkgo Biloba 2-25 dry extract of white pepper 1-15 dry extract of pomegranate pulp 2-20 extract of medlar 2-20 dry powder of pomegranate juice 2-25 folic acid 3-30

A pharmaceutical composition containing dry powder of pine (Pinus) needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive, dry extracts of ginger (Zingiber officinale), turmeric (Curcuma longa), white peony (Paeonia), Rhodiola Rosea (Rhodiola Rosea), apricot (Prunus) seed, oyster mushroom (Pleurotus ostreatus), green tea (Camellia sinensis), Ginkgo Biloba (Ginkgo biloba), white pepper, pomegranate (Punica granatum) pulp, medlar (Mespilus germanica), dry powder of pomegranate (Punica granatum) juice and folic acid, in the following ratio of the components in weight % (w %):

TABLE-US-00001 dry powder of pine needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive 6-24 dry extract of ginger 6-25 dry extract of turmeric 5-24 dry extract of white peony 2-20 dry extract of Rhodiola Rosea 2-20 dry extract of apricot seed 5-20 dry extract of oyster mushroom 10-34 dry extract of green tea 12-35 dry extract of Ginkgo Biloba 2-25 dry extract of white pepper 1-15 dry extract of pomegranate pulp 2-20 extract of medlar 2-20 dry powder of pomegranate juice 2-25 folic acid 3-30

A pharmaceutical composition containing dry powder of pine (Pinus) needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive, dry extracts of ginger (Zingiber officinale), turmeric (Curcuma longa), white peony (Paeonia), Rhodiola Rosea (Rhodiola Rosea), apricot (Prunus) seed, oyster mushroom (Pleurotus ostreatus), green tea (Camellia sinensis), Ginkgo Biloba (Ginkgo biloba), white pepper, pomegranate (Punica granatum) pulp, medlar (Mespilus germanica), dry powder of pomegranate (Punica granatum) juice and folic acid, in the following ratio of the components in weight % (w %):

TABLE-US-00001 dry powder of pine needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive 6-24 dry extract of ginger 6-25 dry extract of turmeric 5-24 dry extract of white peony 2-20 dry extract of Rhodiola Rosea 2-20 dry extract of apricot seed 5-20 dry extract of oyster mushroom 10-34 dry extract of green tea 12-35 dry extract of Ginkgo Biloba 2-25 dry extract of white pepper 1-15 dry extract of pomegranate pulp 2-20 extract of medlar 2-20 dry powder of pomegranate juice 2-25 folic acid 3-30

This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids.

This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids.